Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ARGX

Argen X (ARGX)

Argen X SE
Date:
Sort by:
 Showing the most relevant articles for your search:EU:ARGX
DateTimeSourceHeadlineSymbolCompany
06/21/20244:50PMGlobeNewswire Inc.argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating PolyneuropathyEU:ARGXArgen X SE
06/17/20241:00AMGlobeNewswire Inc.argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024EU:ARGXArgen X SE
06/04/20241:00AMGlobeNewswire Inc.argenx to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceEU:ARGXArgen X SE
05/09/20241:00AMGlobeNewswire Inc.argenx Reports First Quarter 2024 Financial Results and Provides Business UpdateEU:ARGXArgen X SE
05/07/20245:30PMGlobeNewswire Inc.argenx announces results of Annual General Meeting of ShareholdersEU:ARGXArgen X SE
05/07/20241:00AMGlobeNewswire Inc.argenx to Present at BofA Securities 2024 Health Care ConferenceEU:ARGXArgen X SE
05/02/20241:00AMGlobeNewswire Inc.argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024EU:ARGXArgen X SE
04/16/20241:00AMGlobeNewswire Inc.argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune DiseaseEU:ARGXArgen X SE
03/27/20242:00AMGlobeNewswire Inc.argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s DiseaseEU:ARGXArgen X SE
03/26/20244:00PMGlobeNewswire Inc.argenx Announces Annual General Meeting of Shareholders on May 7, 2024EU:ARGXArgen X SE
03/26/20242:00AMGlobeNewswire Inc.argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune ThrombocytopeniaEU:ARGXArgen X SE
03/07/20244:01PMGlobeNewswire Inc.argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual MeetingEU:ARGXArgen X SE
02/29/20241:00AMGlobeNewswire Inc.argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business UpdateEU:ARGXArgen X SE
02/26/20241:00AMGlobeNewswire Inc.argenx to Present at Upcoming Investor ConferencesEU:ARGXArgen X SE
02/22/20241:00AMGlobeNewswire Inc.argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024EU:ARGXArgen X SE
02/20/20241:00AMGlobeNewswire Inc.argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating PolyneuropathyEU:ARGXArgen X SE
01/18/20241:00AMGlobeNewswire Inc.argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia GravisEU:ARGXArgen X SE
01/08/20241:00AMGlobeNewswire Inc.argenx Highlights 2024 Strategic PrioritiesEU:ARGXArgen X SE
01/02/20241:00AMGlobeNewswire Inc.argenx to Present at 42nd Annual J.P. Morgan Healthcare ConferenceEU:ARGXArgen X SE
12/20/20231:00AMGlobeNewswire Inc.argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in PemphigusEU:ARGXArgen X SE
11/28/20231:00AMGlobeNewswire Inc.argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune ThrombocytopeniaEU:ARGXArgen X SE
11/16/20237:40AMGlobeNewswire Inc.argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia GravisEU:ARGXArgen X SE
11/01/20232:00AMGlobeNewswire Inc.argenx to Present at Upcoming Investor ConferencesEU:ARGXArgen X SE
11/01/20232:00AMGlobeNewswire Inc.argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific SessionsEU:ARGXArgen X SE
10/31/20232:00AMGlobeNewswire Inc.argenx Reports Third Quarter 2023 Financial Results and Provides Business UpdateEU:ARGXArgen X SE
10/24/20231:00AMGlobeNewswire Inc.argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023EU:ARGXArgen X SE
09/21/20231:00AMGlobeNewswire Inc.argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia GravisEU:ARGXArgen X SE
09/15/20231:00AMGlobeNewswire Inc.argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia GravisEU:ARGXArgen X SE
08/30/20231:00AMGlobeNewswire Inc.argenx to Present at Upcoming Investor ConferencesEU:ARGXArgen X SE
07/27/20231:00AMGlobeNewswire Inc.argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business UpdateEU:ARGXArgen X SE
 Showing the most relevant articles for your search:EU:ARGX